Lumos Pharma — NewLink Genetics — Q3 2017 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Nov 2, 2017
Slide 1: Third Quarter 2017 Results
NewLink Genetics Corporation Nasdaq: NLNK November 2, 2017 Third Quarter 2017 Results
Slide 2: Agenda
Agenda 2 Introduction Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments & Outlook Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates & Guidance on Timing of Data Eugene P. Kennedy, M.D., Vice President Clinical & Medical Affairs Third Quarter 2017 Fin
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w
Slide 4: Recent Highlights
Recent Highlights Progression toward Pivotal trial in advanced melanoma achieved with parameters of trial design established and reviewed by FDA Updated Phase 2 data for indoximod plus PD-1 checkpoint inhibitor KEYTRUDA® suggest substantial improvement of response rate for advanced melanoma pati
Slide 5: Best Response by Patient with Advanced Melanoma
Best Response by Patient with Advanced Melanoma 5 Significant Depth of Response *Patients that progressed due to new non-target lesions. Note: 1 patient was unevaluable for response due to pleural effusion/collapsed left lung; the patient progressed based on several new non-target lesions. Zakharia
Slide 6: Indoximod Pivotal Phase Study Design
Indoximod Pivotal Phase 3 Study Design Two-Arm, Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study Randomization via an interactive web system Stratified by: ̶ Checkpoint inhibitor (pembro or nivo) ̶ Prior BRAF treatment ̶ Advanced stage disease at randomization Investigator choice
Slide 7: Clinical Collaboration between AstraZeneca and NewLink
Clinical Collaboration between AstraZeneca and NewLink Phase 2 Randomized, Placebo Controlled Trial of IDO plus anti-PDL-1 Statistically powered to compare 4 drug regimen to Standard of Care (SOC) Primary Endpoint: Overall Response Secondary Endpoints: ̶ Overall Survival ̶ Progression Free Sur
Slide 8: Third Quarter 2017 Financial Results
Third Quarter 2017 Financial Results Cash and Equivalents $120.7 million Debt ~$0.3 million YE 2017 Cash (Projected)1 ~$150 million Forecast Quarterly Negative Cash-Flow ~$14-$16 million Shares Outstanding as of October 31,20171 37.1 million 8 1 Includes ~$55 million from an underwritten offering of
Slide 9: Key Takeaways
NewLink Genetics The Phase 3 Pivotal trial for patients with advanced melanoma is our top priority and we continue to work toward our goal of completing accrual by the end of 2018. The AstraZeneca collaboration represents a significant step in our effort to expand the clinical program and differ
Slide 10: Q & A
10 Q & A